Publications by authors named "Jihane Hamdi"

7 Publications

  • Page 1 of 1

Draft Genome Sequence of the Capripoxvirus Vaccine Strain KSGP 0240, Reisolated from Cattle.

Microbiol Resour Announc 2021 Jul 29;10(30):e0044021. Epub 2021 Jul 29.

Research and Development Department, Multi-Chemical Industry, Mohammedia, Morocco.

Control of lumpy skin disease in cattle is based on vaccination with live attenuated vaccines. The Kenyan strain KSGP 0240 is commonly used to vaccinate ruminants against capripox infections, but the conferred protection is still controversial. In this study, we report the draft genome sequence of the vaccine strain KSGP 0240, reisolated from cattle.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1128/MRA.00440-21DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320456PMC
July 2021

Investigation of Post Vaccination Reactions of Two Live Attenuated Vaccines against Lumpy Skin Disease of Cattle.

Vaccines (Basel) 2021 Jun 8;9(6). Epub 2021 Jun 8.

MCI Santé Animale, Mohammedia 28810, Morocco.

Lumpy skin disease virus (LSDV) causes an economically important disease in cattle. The only method for successful control is early diagnosis and efficient vaccination. Adverse effects of vaccination such as local inflammation at the injection site and localized or generalized skin lesions in some vaccinated animals have been reported with live vaccines. The aim of this work was to compare the safety of two lumpy skin disease (LSD) vaccine strains, Kenyan (Kn) Sheep and Goat Pox (KSGP O-240) and LSDV Neethling (Nt) strain, and to determine the etiology of the post-vaccination (pv) reactions observed in cattle. Experimental cattle were vaccinated under controlled conditions with Nt- and KSGP O-240-based vaccines, using two different doses, and animals were observed for 3 months for any adverse reactions. Three out of 45 cattle vaccinated with LSDV Nt strain (6.7%) and three out of 24 cattle vaccinated with Kn strain (12.5%) presented LSD-like skin nodules, providing evidence that the post-vaccination lesions may not be strain-dependent. Lesions appeared 1-3 weeks after vaccination and were localized in the neck or covering the whole body. Animals recovered after 3 weeks. There is a positive correlation between the vaccine dose and the appearance of skin lesions in vaccinated animals; at the 105 dose, 12% of the animals reacted versus 3.7% at the 104 dose. Both strains induced solid immunity when protection was measured by neutralizing antibody seroconversion.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/vaccines9060621DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226854PMC
June 2021

Capripoxvirus Infections in Ruminants: A Review.

Microorganisms 2021 Apr 23;9(5). Epub 2021 Apr 23.

Department of Microbiology, Immunology and Contagious Diseases, Agronomic and Veterinary Institute Hassan II, Madinat Al Irfane, Rabat 6202, Morocco.

Lumpy skin disease, sheeppox, and goatpox are notifiable diseases of cattle, sheep, and goats, respectively, caused by viruses of the Capripoxvirus genus. They are responsible for both direct and indirect financial losses. These losses arise through animal mortality, morbidity cost of vaccinations, and constraints to animals and animal products' trade. Control and eradication of capripoxviruses depend on early detection of outbreaks, vector control, strict animal movement, and vaccination which remains the most effective means of control. To date, live attenuated vaccines are widely used; however, conferred protection remains controversial. Many vaccines have been associated with adverse reactions and incomplete protection in sheep, goats, and cattle. Many combination- and recombinant-based vaccines have also been developed. Here, we review capripoxvirus infections and the immunity conferred against capripoxviruses by their respective vaccines for each ruminant species. We also review their related cross protection to heterologous infections.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/microorganisms9050902DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145859PMC
April 2021

Experimental infection of indigenous North African goats with goatpox virus.

Acta Vet Scand 2021 Mar 4;63(1). Epub 2021 Mar 4.

Department of Research and Development, Multi-Chemical Industry Santé Animale, Lot. 157, Z I, Sud-Ouest (ERAC) B.P.: 278, 28810, Mohammedia, Morocco.

Background: Goatpox is a viral disease caused by infection with goatpox virus (GTPV) of the genus Capripoxvirus, Poxviridae family. Capripoxviruses cause serious disease to livestock and contribute to huge economic losses. Goatpox and sheeppox are endemic to Africa, particularly north of the Equator, the Middle East and many parts of Asia. GTPV and sheeppox virus are considered host-specific; however, both strains can cause clinical disease in either goats or sheep with more severe disease in the homologous species and mild or sub-clinical infection in the other. Goatpox has never been reported in Morocco, Algeria or Tunisia despite the huge population of goats living in proximity with sheep in those countries. To evaluate the susceptibility and pathogenicity of indigenous North African goats to GTPV infection, we experimentally inoculated eight locally bred goats with a virulent Vietnamese isolate of GTPV. Two uninfected goats were kept as controls. Clinical examination was carried out daily and blood was sampled for virology and for investigating the antibody response. After necropsy, tissues were collected and assessed for viral DNA using real-time PCR.

Results: Following the experimental infection, all inoculated goats displayed clinical signs characteristic of goatpox including varying degrees of hyperthermia, loss of appetite, inactivity and cutaneous lesions. The infection severely affected three of the infected animals while moderate to mild disease was noticed in the remaining goats. A high antibody response was developed. High viral DNA loads were detected in skin crusts and nodules, and subcutaneous tissue at the injection site with cycle threshold (Ct) values ranging from 14.6 to 22.9, while lower viral loads were found in liver and lung (Ct = 35.7 and 35.1). The results confirmed subcutaneous tropism of the virus.

Conclusion: Clinical signs of goatpox were reproduced in indigenous North African goats and confirmed a high susceptibility of the North African goat breed to GTPV infection. A clinical scoring system is proposed that can be applied in GTPV vaccine efficacy studies.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13028-021-00574-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931584PMC
March 2021

Experimental evaluation of the cross-protection between Sheeppox and bovine Lumpy skin vaccines.

Sci Rep 2020 06 1;10(1):8888. Epub 2020 Jun 1.

Research and Development Virology, Multi-Chemical Industry, Lot. 157, Z I, Sud-Ouest (ERAC) B.P.: 278, Mohammedia, 28810, Morocco.

The Capripoxvirus genus includes three agents: Sheeppox virus, Goatpox virus and Lumpy skin disease virus. Related diseases are of economic importance and present a major constraint to animals and animal products trade in addition to mortality and morbidity. Attenuated vaccines against these diseases are available, but afforded cross-protection is controversial in each specie. In this study, groups of sheep, goats and cattle were vaccinated with Romania SPPV vaccine and challenged with corresponding virulent strains. Sheep and cattle were also vaccinated with Neethling LSDV vaccine and challenged with both virulent SPPV and LSDV strains. Animals were monitored by clinical observation, rectal temperature as well as serological response. The study showed that sheep and goats vaccinated with Romania SPPV vaccine were fully protected against challenge with virulent SPPV and GTPV strains, respectively. However, small ruminants vaccinated with LSDV Neethling vaccine showed only partial protection against challenge with virulent SPPV strain. Cattle showed also only partial protection when vaccinated with Romania SPPV and were fully protected with Neethling LSDV vaccine. This study showed that SPPV and GTPV vaccines are closely related with cross-protection, while LSDV protects only cattle against the corresponding disease, which suggests that vaccination against LSDV should be carried out with homologous strain.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-65856-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264126PMC
June 2020

Development and Evaluation of an Inactivated Lumpy Skin Disease Vaccine for Cattle.

Vet Microbiol 2020 Jun 18;245:108689. Epub 2020 Apr 18.

Research and development Virology, Multi-Chemical Industry, Lot. 157, ZI Sud-Ouest (ERAC) B.P: 278, Mohammedia 28810, Morocco.

Lumpy skin disease (LSD) of cattle is caused by a virus within Capripoxvirus genus. It leads to huge economic losses in addition to trade and animal movement limitation. Vaccination is the only economically feasible way to control this vector-borne disease. Only live attenuated vaccines have been used so far and no inactivated vaccine has been developed nor tested in cattle. In this study, we developed an inactivated oily adjuvanted vaccine based on Neethling strain and tested it on cattle. Selected criteria of appreciation were safety, antibody response by Virus Neutralization and protection through challenge. A field trial was also performed in Bulgaria. The vaccine was safe and did not cause any adverse reaction, high level of specific antibodies was obtained starting from day 7 post-vaccination and protection against virulent challenge strain that caused typical disease in control animals was total. Induced protection was similar to that obtained with live vaccine, without any adverse effect. In addition, the field study confirmed safety and efficacy of the vaccine, which did not show any adverse reaction and induced a high level of antibodies for up to one year. General prophylaxis based on inactivated vaccine could be of great benefit in endemic countries or at risk regions.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vetmic.2020.108689DOI Listing
June 2020

Thermal Stability Study of Five Newcastle Disease Attenuated Vaccine Strains.

Avian Dis 2016 12;60(4):779-783

Research and Development Department, Multi-Chemical Industry, Lot. 157, Z I, Sud-Ouest (ERAC) B.P.: 278, Mohammedia 28810, Morocco.

Newcastle disease (ND) is a big concern throughout the world because of the devastating losses that can occur with commercial and backyard poultry. The major problem in many countries is the loss of the vaccine's effectiveness due to inadequate use or storage conditions, particularly in hot climates. In the present study, stability of the five, most-used NDV vaccine strains (I-2, LaSota, B1, Clone 30 [C30], and VG-GA) was tested comparatively at different storage temperatures (4 and 37 C for the freeze-dried form and 4, 24, 37, and 45 C for the freeze-dried vaccine reconstituted in diluents). The vaccine stability was evaluated by the cumulative infectious titer drop and the theoretical shelf life at particular temperatures. Results showed that I-2 and LaSota are the most stable vaccine strains compared to B1, C30, and VG-GA; they registered the lowest titer drops and the longest shelf life whether at cool, high, or room temperatures and for both freeze-dried and reconstituted vaccines.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1637/11426-042116-Reg.1DOI Listing
December 2016
-->